Patents by Inventor Philip W. Gold

Philip W. Gold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of neuroendocrine regulation of affective disorders
    Patent number: 6313098
    Abstract: Methods of treating an affective disorder in an individual are disclosed. Affective disorders include major depression, melancholic and atypical subtypes, and dysthymia.
    Type: Grant
    Filed: July 18, 2000
    Date of Patent: November 6, 2001
    Assignees: Beth Israel Deaconess Medical Center, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey S. Flier, Julio Licinio de Castro Paixao, Philip W. Gold, Ma-Li Wong
  • Methods of neuroendocrine regulation of affective disorders
    Patent number: 5866547
    Abstract: Methods of treating an affective disorder in an individual are disclosed. Affective disorders include major depression, melancholic and atypical subtypes, and dysthymia.
    Type: Grant
    Filed: January 20, 1998
    Date of Patent: February 2, 1999
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Jeffrey S. Flier, Julio Licinio De Castro Paixao, Philip W. Gold, Ma-Li Wong
  • Evaluative means for detecting inflammatory reactivity
    Patent number: 5348729
    Abstract: The present invention is directed to a method for testing the susceptibility of a mammal to inflammatory diseases which comprises the steps of:administering to a mammal a compound selected from the group consisting of Type 1 mineralocorticoid receptor antagonists, opiate antagonists, estrogen antagonists or mixed estrogen agonists/antagonists, progesterone agonists; or a combination of an estrogen antagonist with one or a combination of a Type I glucocorticoid receptor antagonist, a Type II glucocorticoid agonist or a progesterone agonist which is effective in stimulating the hypothalamic-pituitary-adrenal (HPA) axis; andmeasuring the level of at least one hormone secreted by the hypothalamus, pituitary or adrenal glands of said mammal.The present invention is also directed to methods of treating inflammatory diseases.
    Type: Grant
    Filed: May 5, 1992
    Date of Patent: September 20, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Esther M. Sternberg, Philip W. Gold, Samuel W. Page
  • Evaluative means for detecting inflammatory reactivity
    Patent number: 5209920
    Abstract: Inbred Lewis (LEW/N) female rats develop an arthritis in response to Group A streptococcal cell wall peptidoglycanpolysaccharide (SCW) which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats, on the other hand, do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity between the two strains, the function of the hypothalamic-pituitary-adrenal axis and its ability to modulate the development of the inflammatory response was studied. It has been found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma ACTH and corticosterone responses to SCW, recombinant human Interleukin-1 alpha (IL-1 alpha), the serotonin agonist, quipazine, and synthetic rat corticotropin-releasing hormone (CRH). In addition, LEW/N rats compared to F344/N rats had smaller adrenal glands and larger thymuses. Treatment of LEW/N rats with replacement doses of dexamethasone decreased the severity of their SCW-induced arthritis.
    Type: Grant
    Filed: September 25, 1989
    Date of Patent: May 11, 1993
    Assignee: The United States of America as represented by the United States Department of Health and Human Services
    Inventors: Esther M. Sternberg, Ronald L. Wilder, Philip W. Gold, George P. Chrousos
  • Evaluative means for detecting inflammatory reactivity
    Patent number: 5006330
    Abstract: Inbred Lewis (LEW/N) female rats develop an arthritis in response to Group A streptococcal cell wall peptidoglycanpolysaccharide (SCW) which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats, on the other hand, do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity between the two strains, the function of the hypothalamic-pituitary-adrenal axis and its ability to modulate the development of the inflammatory response was studied. It has been found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma ACTH and corticosterone responses to SCW, recombinant human Interleukin-1 alpha (IL-1 alpha), the serotonin agonist, quipazine, and synthetic rat corticotropin-releasing hormone (CRH). In addition, LEW/N rats compared to F344/N rats had smaller adrenal glands and larger thymuses. Treatment of LEW/N rats with replacement doses of dexamethasone decreased the severity of their SCW-induced arthritis.
    Type: Grant
    Filed: November 30, 1988
    Date of Patent: April 9, 1991
    Assignee: The United States of America as represented by the of the Department of Health and Human Services
    Inventors: Esther M. Sternberg, Ronald L. Wilder, George P. Chrousos, Philip W. Gold